2008年1月29日 · To explore whether loss of DNA mismatch repair (MMR) function is involved in AML, we screened two key MMR genes, MSH2 and MLH1, for mutations and promoter hypermethylation in leukemia...

2003年11月1日 · DNA mismatch repair (MMR) is an important replication error avoidance mechanism that prevents mutation. The association of defective MMR with familial and sporadic gastrointestinal and endometrial cancer has been acknowledged for some years.

2020年3月3日 · BCR-ABL1 transcript level ≤0.1% is defined as major molecular response (MMR) or MR 3. A BCR-ABL1 transcript level ≤0.01% or undetectable disease in cDNA with >10,000 ABL1...

2021年1月5日 · Drug resistance is a key factor in the treatment failure of acute myeloid leukemia (AML). Nuclear factor E2-related factor 2 (Nrf2) plays a crucial role in tumor chemotherapy resistance....

2024年3月22日 · Researchers have established in glioma that mismatch repair (MMR) loss confers resistance to TMZ, and reported studies also show evidence of MMR loss in refractory or relapsed AML patients. Thus, we developed numerous MMR-deficient isogenic AML cell lines in an MGMT+/– background and observed MMR loss-mediated resistance to TMZ and abrogation ...

To explore whether loss of DNA mismatch repair (MMR) function is involved in AML, we screened two key MMR genes, MSH2 and MLH1, for mutations and promoter hypermethylation in leukemia specimens from 53 AML patients and blood from 17 non-cancer controls.

2016年11月7日 · 初诊 AML 的患者治疗失败由 TRM 或耐药所致，TRM 指患者在未达到缓解或缓解过程中的死亡，而耐药指缓解后复发或在一定时间内未达缓解，该特定时间可能因患者的 AML 生物学特点各不相同，因此 TRM 和耐药之间可能有重叠。 1. TRM 相关因素. 逐渐有人认识到 TRM 主要与年龄相关，但体能状况在预测 TRM 时较年龄则更加重要，在预测 TRM 的多变量模型中除去年龄，对其预测能力影响甚微，因此，与年龄相关的不同合并症对 TRM 的影响还在研 …

2004年8月1日 · Cellular resistance to thiopurines is associated with DNA mismatch repair (MMR) deficiency. We demonstrate that thiopurine treatment of human cells in vitro selects variants with defective MMR.

2012年11月16日 · We sought to improve outcome in patients with t(8;21) acute myeloid leukemia(AML) in first complete remission (CR) by applying risk-directed therapy that was based on measurements of minimal residual disease (MRD) by quantitative PCR during treatment.

Background: Microsatellite instability (MSI) is caused by defects in DNA mismatch repair (MMR) components. Inactivation of any MMR gene(s), including hMLH1, hMSH2, hMSH6, and hPMS2, can result in MSI. Immunohistochemistry (IHC) is a sensitive and specific screening tool for MSI that can detect loss of expression of one or more MMR components.